Shots:
- ALX Oncology presented data from exploratory analyses of P-Ib/II trial assessing evorpacept + Ziihera in pts with heavily pre-treated HER2+ mBC, all of whom had received prior Enhertu therapy, at ESMO Breast Cancer 2026
- Exploratory analyses in 24 pts treated with evorpacept + Ziihera at dosages of 20mg/kg (n=3) or 30mg/kg (n=21), showed a 33% cORR & mPFS of 3.6mos. overall, while pts with ccHER2-positive disease (n=10) achieved a higher cORR of 60% & mPFS of 8.3mos.
- Among pts (n=5) with ccHER2+ disease & high CD47 expression, all responded to the combination (100% cORR: 1 CR, 4 PRs), with mDOR of 20.2mos. & mPFS of 22.1mos., vs a 25% cORR & 3.4mos. mPFS in pts with ccHER2+ disease & low CD47 expression
Ref: Globenewswire | Image: ALX Oncology | Press Release
Related News: Bayer Reports P-III (REVEAL) Trial Data on Iodine 124 evuzamitide to Diagnose Cardiac Amyloidosis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
